Trial Profile
Phase II Study of Combination Therapy with OBP-301 and Radiotherapy in Patients with Locally Advanced Esophageal Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2023
Price :
$35
*
At a glance
- Drugs Suratadenoturev (Primary)
- Indications Adenocarcinoma; Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 17 Oct 2023 Primary endpoint (L-CR (Local Complete Response) rate) has been met as per Oncolys Biopharma Media Release
- 17 Oct 2023 Results published in the Oncolys Biopharma Media Release
- 04 Aug 2023 According to a Oncolys Biopharma media release, The results for this trial are expected to be available in October 2023.